🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China flag China · Delayed Price · Currency is CNY
8.02
-0.49 (-5.76%)
Nov 20, 2026, 3:04 PM CST

SHE:301060 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
816.28759.5828.95861.2665.81351.96
Trading Asset Securities
-----420.93
Cash & Short-Term Investments
816.28759.5828.95861.2665.81772.89
Cash Growth
9.57%-8.38%-3.74%29.35%-13.85%45.09%
Accounts Receivable
551.84686.13808.631,0332,249819.61
Other Receivables
4.874.9214.546.0811.837.89
Receivables
556.71691.05823.171,0402,261827.5
Inventory
225.68269.81306.09367.71401.52139.44
Prepaid Expenses
---0.118.45-
Other Current Assets
25.1731.4540.4357.9751.5627.23
Total Current Assets
1,6241,7521,9992,3273,3891,767
Property, Plant & Equipment
390434.04482.58509.74220.96241.11
Long-Term Investments
0.760.981.7614.0616.74-
Goodwill
7.667.667.6615.2417.6430.09
Other Intangible Assets
20.8723.6724.4526.513.0614.81
Long-Term Accounts Receivable
-0.960.25---
Long-Term Deferred Tax Assets
43.2959.6673.8248.9530.1313.39
Long-Term Deferred Charges
13.7312.6530.0437.1749.632.05
Other Long-Term Assets
1.710.774.128.6710.166.97
Total Assets
2,1022,2922,6232,9873,7472,105

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
291.95402.62388.99502.36858.69253.03
Accrued Expenses
16.4850.2761.9850.07253.6490.24
Short-Term Debt
-25.0195.11214.59182.162
Current Portion of Long-Term Debt
8.8128.9915.1415.15--
Current Portion of Leases
-8.0512.0810.7716.8113.67
Current Income Taxes Payable
7.233.6612.549.7351.7628.91
Current Unearned Revenue
39.597.2415.126.628.739.28
Other Current Liabilities
18.535.3214.6413.5522.0315.85
Total Current Liabilities
382.58531.18615.59822.831,414412.98
Long-Term Debt
87104133.7145.77--
Long-Term Leases
4.085.3818.2721.0745.6250.03
Long-Term Unearned Revenue
4.076.7110.4211.9414.682.66
Other Long-Term Liabilities
-0.1225.025.09--
Total Liabilities
477.73647.398031,0071,474465.67

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
400.52400.52400.52400.52400.52400.52
Additional Paid-In Capital
556.07554.76553.96553.96553.96552.8
Retained Earnings
625.97616.86727.31836.751,109611.62
Treasury Stock
-23.01-23.01-23.01-10.26--
Comprehensive Income & Other
-0.65-0.65-0.65-0.65--
Total Common Equity
1,5591,5481,6581,7802,0631,565
Minority Interest
65.2596.35162.21199.85209.4974.88
Shareholders' Equity
1,6241,6451,8201,9802,2731,640
Total Liabilities & Equity
2,1022,2922,6232,9873,7472,105

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
99.89171.44274.29407.35244.5965.7
Net Cash (Debt)
716.39588.06554.66453.85421.22707.19
Net Cash Growth
32.64%6.02%22.21%7.75%-40.44%32.75%
Net Cash Per Share
1.841.531.371.121.052.01
Filing Date Shares Outstanding
398.52398.52398.52399.77400.52400.52
Total Common Shares Outstanding
398.52398.52398.52399.77400.52400.52
Working Capital
1,2411,2211,3831,5041,9751,354
Book Value Per Share
3.913.894.164.455.153.91
Tangible Book Value
1,5301,5171,6261,7392,0331,520
Tangible Book Value Per Share
3.843.814.084.355.073.80
Buildings
-334.17337.04333.0258.7728.94
Machinery
-305.35332.87342296.39290.65
Construction In Progress
-10.940.999.52-16.98